PHK
RLMD icon

Point72 Hong Kong’s Relmada Therapeutics RLMD Stock Holding History

Point72 Hong Kong’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-773
Closed -$15K – 2352
2022
Q2 		$15K Buy
+773
New +$16.9K ﹤0.01% 1614
2020
Q3 		– Sell
-46
Closed -$2K – 1479
2020
Q2 		$2K Buy
+46
New +$1.95K ﹤0.01% 1078

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Point72 Hong Kong's RLMD Position: Q3 2022 in Review

Point72 Hong Kong sold out of Relmada Therapeutics (RLMD) in Q3 2022, closing a stake of 773 shares — an estimated $15K sold.

Point72 Hong Kong first reported a position in RLMD in Q2 2020 and held it in 2 quarters. The position peaked at $15K in Q2 2022. 134 funds tracked by Wall St. Rank hold RLMD as of Q3 2022.

  • Point72 Hong Kong reported no remaining Relmada Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 773 Relmada Therapeutics shares in Q3 2022, an estimated $15K.
  • Point72 Hong Kong first reported a position in Relmada Therapeutics in Q2 2020 and held it in 2 quarters.
  • Point72 Hong Kong's Relmada Therapeutics position peaked at $15K in Q2 2022.
  • 134 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.